Drug Approval | June 27, 2025
SMS Pharmaceuticals completes USFDA inspection at Central Laboratory Analytical Services
The inspection concluded with zero Form 483 observations
The inspection concluded with zero Form 483 observations
This significant milestone enhances our global regulatory standing
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
With this, the company can start selling Ibuprofen in the European markets.
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
